SUPN - Supernus Pharmaceuticals EPS beats by $0.17 beats on revenue; updates full year guidance
Supernus Pharmaceuticals (NASDAQ:SUPN): Q3 GAAP EPS of $0.40 beats by $0.17. Revenue of $148.5M (-4.3% Y/Y) beats by $6.38M. Press Release Full Year 2021 Financial Guidance: Total revenues of $550M - $570M (prior $550M - $580M) vs. consensus of $560.68M; Operating earnings of $90M- $95M (prior$70M - $90M )and Effective Tax Rate of 28% - 31%.
For further details see:
Supernus Pharmaceuticals EPS beats by $0.17, beats on revenue; updates full year guidance